MedTrace Logo

Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

NCT00654030 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-04-09

Study results available
· View outcomes & findings →

Summary

Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells.

The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial definitive therapies.

Conditions

Interventions

DRUG

1650-G Vaccine

.6ml injection administered intradermally in the thigh at week 0 and week 4

Sponsors & Collaborators

  • Kentucky Lung Cancer Research Program

    collaborator OTHER

  • Edward Hirschowitz

    lead OTHER

Principal Investigators

  • Edward A Hirschowitz, MD · University of Kentucky

  • John R Yannelli, PhD · University of Kentucky

  • Goetz H Kloecker, MD · University of Louisville

  • Thomas R Baeker, MD · Commonwealth Cancer Center

  • Dattatraya S Prajapati, MD · Owensboro Medical Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00654030 on ClinicalTrials.gov